Shire beats expectations, with sales up 34% driven by Adderall XR and Elaprase

5 August 2007

UK drugmaker Shire not only beat consensus forecasts with its second-quarter 2007 results, but also upped its guidance for full-year sales growth of not less than 25% versus 20% projected earlier.

The company reported a solid 34% rise in product sales to $504.0 million for the period, with total revenues up 31% to $575.0 million. However, largely due to its $2.6 billion acquisition of US firm New River earlier this year (Marketletters passim), Shire posted a net loss of $1.81 billion, or $0.33 per share.

Shire, the UK's third largest pharmaceutical firm, saw sales of its lead drug, the attention-deficit disorder agent Adderall XR (mixed amphetamine salts) advance 16% to $255.1 million, with an average US market share of 26%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight